A fc-vegf chimeric fusion enhances pd-l1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment

HIGHLIGHTS

• who: Cheng-Liang Kuo from the National Institute of Research, National Health Research Institutes, Zhunan, Miaoli, Taiwan Yang Ming Chiao Tung University, Hsinchu, Taiwan have published the paper: A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment, in the Journal: (JOURNAL)
• what: The authors showed that antibody drug arrests excess angiogenesis and tumor growth through vascular normalization using in vitro and in vivo studies. The aim of this study was to evaluate the efficacy of FcVFD on angiogenesis and tumorigenesis in_vitro and in_vivo and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.